A New York based biotech organized around development of solutions for tackling drug-resistant breast cancer, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1. Management assert that the firm's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
